Dongfeng Wu, Ph.D.
Education:
B.S., Probability and Statistics, Peking University, P.R. China; 1990.
M.S., Probability and Statistics, Peking University, P.R. China; 1993.
M.S., Computer Science, University of California, Santa Barbara, 1999.
Ph.D., Statistics, University of California, Santa Barbara. 1999.
Curriculum Vitae
Current Positions:
Associate Professor, Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences
Member, Care and Control Program, James Graham Brown Cancer Center
Contact Information:
School of Public Health and Information Sciences
485 E. Gray Street
Louisville, KY 40202, USA.
Website:
http://louisville.edu/sphis/directory/dongfeng-wu-phd
Research Description:
My main research area is in probability modeling and statistical inferences in cancer screening. Besides that, I am interested in Bayesian inference, statistical decision theory, time series, smoothing spline, wavelet regression and all kinds of statistical methods in medical research.
Literature Cited:
- Wu D, Kafadar K, Rai SN. Inference of long-term screening outcomes for individuals with screening histories. Statistics and Public Policy 2018;5(1):1-10. https://dio.org/10.1080/2330443X.2018.1438939.
- Liu R, Perez A, Wu D. Estimation of lead time via low-dose CT in the National Lung Screening Trial. Journal of Healthcare Informatics Research. Published online June 12, 2018, https://doi.org/10.1007/s41666-018-0027-8
- Liu R, Gaskin JT, Mitra R, Wu D. A review of estimation of key parameters and lead time in cancer screening. Revista Colombiana de Estadistica (Colombian Journal of Statistics) 2017;40(2):263-78. DOI: http://dx.doi.org/10.15446/rce.v40n2.60642.
- Wang D, Levitt B, Riley T, Wu D. Estimation of sojourn time and transition probability of lung cancer for smokers using the PLCO data. Journal of Biometrics and Biostatistics 2017;8:360. doi: 10.4172/2155-6180.1000360.
- Wu D, Liu R, Levitt B, Riley T, Baumgartner, KB. Evaluating long-term outcomes via computed tomography in lung cancer screening. Journal of Biometrics and Biostatistics 2016;7(3):313. doi:10.4172/2155-6180.1000313.
- Kim S, Wu D. Estimation of sensitivity depending on sojourn time and time spent in preclinical state. Statistical Methods in Medical Research 2016;25(2):728-40. doi: 10.1177/0962280212465499.
- Liu R, Levitt B, Riley T, Wu D. Bayesian estimation of the three key parameters in CT for the National Lung Screening Trial data. Journal of Biometrics and Biostatistics 2015;6:263. doi: 10.4172/2155-6180.1000263
- Kim S, Jang H, Wu D, Abrams J. A Bayesian nonlinear mixed-effects disease progression model. Journal of Biometrics and Biostatistics 2015;6:271. doi: 10.4172/2155-6180.1000271.
- Kendrick SK, Rai SN, Wu D. Simulation study for the sensitivity and mean sojourn time specific lead time in cancer screening when human lifetime is a competing risk. Journal of Biometrics and Biostatistics 2015;6(4):247. doi: 10.4172/2155-6180.1000247.
- Wu D, Kafadar K, Rosner GL. Inference of long term effects and over-diagnosis in periodic cancer screening. Statistica Sinica 2014;24(2):815-31.
- Chen Y, Erwin D, Wu D. Over-diagnosis in lung cancer screening using the MSKC-LCSP data. Journal of Biometrics and Biostatistics 2014;5(4):201. doi: 10.4172/2155-6180.1000201.
- Jang H, Kim S, Wu D. Bayesian lead time calculation for the Johns Hopkins Lung Project data. Journal of Epidemiology and Global Health 2013 Sep;3(3):157-73. PMID: 23932058. doi: 10.1016/j.jegh.2013.05.001.
- Kim S, Erwin D, Wu D. Efficacy of dual lung cancer screening by chest x-ray and sputum cytology using Johns Hopkins lung project data. Journal of Biometrics and Biostatistics 2012;3(4):139-42. doi:10.4172/2155-6180.1000139.
- Wu D, Kafadar, K, Rosner GL, Broemeling LD. The lead time distribution when lifetime is subject to competing risks in cancer screening. The International Journal of Biostatistics 2012;8(1):Article 6. doi: 10.1515/1557-4679.1363. PMID: 226111589.
- Luo D, Cambon AC, Wu D. Evaluating long term effect of FOBT in colon cancer screening. Cancer Epidemiology 2012 Feb;36(1):e54-e60. doi: 10.1016/j.canep.2011.09.011. PMID: 22075536.
- Wu D, Erwin D, Kim S. Projection of long-term outcomes using X-rays and pooled cytology in lung cancer screening. Open Access Medical Statistics 2011 Aug 2;1:13-19. doi: 10.2147/OAMS.S22987.
- Wu D, Perez A. A limited review of over-diagnosis methods and long term effects in breast cancer screening. Oncology Reviews 2011 Sep 1;5(3):143-7. PMID: 21927651. PMCID: PMC3171741.
- Shows J, Wu D. Inferences for the lead time in breast cancer screening trials under a stable disease model. Cancers (Basel) 2011;3(2):2131-40. doi: 10.3390/cancers3022131. PMID: 24212799. PMCID: PMC3757407.
- Wu D, Erwin D. Rosner GL. Sojourn time and lead time projection in lung cancer screening. Lung Cancer 2011 Jun;72(3):322-6. PMID: 21075475. PMCID: PMC4839299.
- Chen Y, Brock G, Wu D. (2010). Estimating key parameters in periodic breast cancer screening - application to the Canadian National Breast Screening Study data. Cancer Epidemiology 2010 Aug 34(4):429-33. doi: 10.1016/j.canep.2010.04.001. PMID: 20434974. PMCID: PMC2910214.
- Wu D, Erwin D, Rosner GL. A projection of benefits due to fecal occult blood test for colorectal cancer. Cancer Epidemiology 2009 Oct;33(34):212-5. doi: 10.1016/j.canep.2009.08.001. PMID: 19733140. PMCID: PMC2773467.
- Wu D, Erwin D, Rosner GL. Estimating key parameters in FOBT screening for colorectal cancer. Cancer Causes and Control 2009 Feb;20(1):41-6. PMID: 18704710. PMCID: PMC2773467.
- Wu D, Cariño RL, Wu X. When sensitivity is a function of age and time spent in the preclinical state in periodic cancer screening. Journal of Modern Applied Statistical Methods 2008;7(1):297-303.
- Wu D, Rosner GL, Broemeling LD. Bayesian inference for the lead time in periodic cancer screening. Biometrics 2007;63(3):873–80. PMID: 17077868. PMCID: PMC1513186.
- Wu D, Rosner GL, Broemeling LD. MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening. Biometrics 2005;61(4):1056-63. PMID: 16401279. PMCID: PMC1540406.